多重用药对老年心脏代谢多病共存者有益还是有害?香港与欧洲研究的汇总分析
该研究汇总香港、以色列及17个欧洲国家社区居住老年人的纵向数据,基线评估于2015至2018年完成,并于1–2年随访复评。在44 818名参与者(平均年龄69.6岁)中,28.3%存在多重用药、34.8%患心脏代谢多病共存;多重用药与住院和衰弱恶化风险升高相关,但在多病共存者中这种风险未见叠加。结论认为多重用药对心脏代谢多病共存老年人危害相对较小,但仍有危害,应优化处方。
要点
- 多重用药(同时使用≥5种药物)与住院及衰弱恶化风险升高相关。
- 多病共存与多重用药同时存在时,风险未见叠加。
- 随心脏代谢疾病数量增加,多重用药的关联效应减弱但仍具统计学意义。
核心结论
- 多重用药对心脏代谢多病共存老年人的危害相对较小,但仍有危害,医生应无论疾病数量多少都优化处方。
- 卫生政策制定者和研究者需在住院风险预测和衰弱量表开发中考虑多病共存与多重用药的相互关系。
研究设计与样本
- 汇总香港、以色列和17个欧洲国家社区居住老年人的纵向数据,基线评估于2015至2018年,1–2年随访复评,采用回归分析。
- 共纳入44 818名参与者,平均年龄69.6岁。
主要发现
- 28.3%的参与者存在多重用药,34.8%患心脏代谢多病共存。
- 仅多病共存者住院和衰弱恶化的调整比值比(AOR)分别为1.10和1.26;仅多重用药者分别为1.57和1.68。
- 多病共存与多重用药合并时未呈叠加风险,住院和衰弱恶化的AOR分别为1.53和1.47。
- 分层分析中,随着心脏代谢疾病数量增加,多重用药与住院和衰弱的关联减弱但仍具统计学意义。
临床怎么用
- 对心脏代谢多病共存的老年患者,不应因疾病数量多而放松处方优化,多重用药仍与住院和衰弱恶化风险升高相关。
- 评估老年患者住院风险与衰弱时,应同时考虑多病共存与多重用药的相互关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Physicians often prescribe high numbers of medications for managing multiple cardiometabolic diseases. It is questionable whether polypharmacy (concurrent use of five or more medications) is beneficial or detrimental for older adults with cardiometabolic multimorbidity (co-occurrence of two or more diseases). OBJECTIVE: To examine combined effects of multimorbidity and polypharmacy on hospitalization and frailty and to determine whether effect sizes of polypharmacy vary with numbers of cardiometabolic diseases. METHODS: We pooled longitudinal data of community-dwelling older adults in Hong Kong, Israel, and 17 European countries. They completed questionnaires for baseline assessment from 2015 to 2018 and reassessment at 1-2-year follow-up. We performed regression analyses to address the objective. RESULTS: Among 44 818 participants (mean age: 69.6 years), 28.3% had polypharmacy and 34.8% suffered from cardiometabolic multimorbidity. Increased risks of hospitalization and worsening frailty were found in participants with 'multimorbidity alone' [adjusted odds ratio (AOR) 1.10 and 1.26] and 'polypharmacy alone' (AOR 1.57 and 1.68). With 'multimorbidity and 'polypharmacy' combined, participants were not at additive risks (AOR 1.53 and 1.47). In stratified analysis, with increasing numbers of cardiometabolic diseases, associations of polypharmacy with hospitalization and frailty were attenuated but remained statistically significant. CONCLUSION: Polypharmacy is less detrimental, yet still detrimental, for older adults living with cardiometabolic multimorbidity. Physicians should optimize prescription regardless of the number of diseases. Health policymakers and researchers need to consider their interrelationship in hospitalization risk predictions and in developing frailty scales.
引用
- Cheung JTK, Yu R, Woo J, et al. Is polypharmacy beneficial or detrimental for older adults with cardiometabolic multimorbidity? Pooled analysis of studies from Hong Kong and Europe. Fam Pract. 2020. PMID: 32596732. doi:10.1093/fampra/cmaa062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。